Recently Launched!
Check out Investor Copilot custom GPT, which lets you enjoy ChatGPT functionality with recent financial information
Conversationally interact with ChatGPT to now analyze updated prices, technical indicators, financial statements, macro-economic/company news & more for Stocks, ETFs & Cryptos
Conversationally interact with ChatGPT to now analyze updated prices, technical indicators, financial statements, macro-economic/company news & more for Stocks, ETFs & Cryptos
[ALNY] Alnylam Pharmaceuticals Inc - Total Non-Current Liabilities
Data updated 2023-Sep-23 (Saturday)Note: Detailed Statistics for Total Non-Current Liabilities in Balance Sheet for Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] with frequency distribution chart that analyze trends & history . Total Non-Current Liabilities are obligations of Company due after one year. View Balance Sheet for broader context
Share
Quarterly Total Non-Current Liabilities values for Alnylam Pharmaceuticals Inc are rounded to enhance readability
| 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sep | 2022-Jun | 2022-Mar | |
|---|---|---|---|---|---|---|
| Total Non-Current Liabilities | 3.02 B | 2.98 B | 2.94 B | 2.83 B | 2.5 B | 2.43 B |
| Sequential Quarter Growth | +1.5% | +1.4% | +3.8% | +13.4% | +2.9% | +2.8% |
| Quarter-on Quarter Growth | +21.1% | +22.8% | +24.5% | +34.4% | +18.8% | +32.3% |
Annual Total Non-Current Liabilities values for Alnylam Pharmaceuticals Inc are rounded to enhance readability
| 2022-Dec | 2022-Jan | 2021-Jan | 2020-Jan | 2019-Jan | 2018-Jan | |
|---|---|---|---|---|---|---|
| Total Non-Current Liabilities | 2.94 B | 2.94 B | 2.36 B | 1.81 B | 603 M | 94 M |
| Year-on-Year Growth | 0.0% | +24.5% | +30.6% | +199.5% | +541.5% | +11.9% |
| 2-yr CAGR | +11.6% | +27.5% | +97.8% | +338.3% | +167.9% | |
| 3-yr CAGR | +17.6% | +69.5% | +192.8% | +178.1% | ||
| 4-yr CAGR | +48.6% | +136.4% | +130.2% | |||
| 5-yr CAGR | +99.0% | +103.6% |
Frequency distribution of quarterly Total Non-Current Liabilities values from 2016-Dec-31 grouped into buckets. Latest Total Non-Current Liabilities value is 3.02 Billion as of 2023-Jun-30
Subsequent stock performance post earnings date till next announcement for Alnylam Pharmaceuticals Inc mapped with quarterly Total Non-Current Liabilities values reported at that time. Most recent value denoted with star
Select frequency and calculation type for Total Non-Current Liabilities above for vertical axis in scatter chart. Additionally choose type of performance for horizontal axis
Bayesian (Conditional Probability) analysis for Alnylam Pharmaceuticals Inc with subsequent post-earnings performance given Total Non-Current Liabilities values. Analysis uses quarterly data and subsequent relative performance benchmarked to S&P 500 index. Most recent quarter is denoted with a star and corresponding partial performance is excluded from calculations
| Underperform (relative perf.) | Outperform (relative perf.) | |
|---|---|---|
| Total Non-Current Liabilities - Low | 44% | 56% |
| Total Non-Current Liabilities - Medium | 44% | 56% |
| Total Non-Current Liabilities - High | 63% | 38% |
| Total Non-Current Liabilities (Sequential growth %) - Low | 38% | 63% |
| Total Non-Current Liabilities (Sequential growth %) - Medium | 50% | 50% |
| Total Non-Current Liabilities (Sequential growth %) - High | 63% | 38% |
| Total Non-Current Liabilities (QoQ growth %) - Low | 43% | 57% |
| Total Non-Current Liabilities (QoQ growth %) - Medium | 57% | 43% |
| Total Non-Current Liabilities (QoQ growth %) - High | 57% | 43% |
Related to Alnylam Pharmaceuticals Inc
Information for Alnylam Pharmaceuticals Inc
Current Detail : Recent daily/monthly performance & benchmark comparison
Historical Detail : Historical performance & related information using Time Machine
Financial Statements : Analyze Income Statement, Balance Sheet & Cashflow Statement and also compare with peers Currently Viewing
Bayesian Statement Classifier : Investigate historical financial statements to make probabalistic predictions using Artificial Intelligence
Anomaly Detection : Investigate unusual recent performance & technicals with historical context using AI
Historical Seasonality : Seasonal performance by calendar months
Technical History : Popular Technical indicator trends (RSI, MACD etc.)
Metric Deciles : Contextualizing recent performance & technical levels into historical decile buckets
Dollar Cost Averaging : Dollar Cost Average (DCA) over time in your portfolio
Moving Averages : Key Simple & Exponential Moving Averages
Historical Analogues : Insights from closest historical matches to recent performance using Artificial Intelligence
Chart Pattern Matching : Insights from similar historical charts to recent chart using Artificial Intelligence
News Stories : News stories on 2025-May-13 on Google
SEC Reports : Quarterly reports around 2025-May-13 on SEC Edgar
Compare Alnylam Pharmaceuticals Inc with other assets
Market Performance : Recent performance across covered assets
Historical Performance : Prior & Subsequent performance across assets on a historical date
Market Technicals : Technical indicator levels across covered assets
Market Seasonality : Seasonal performance by calendar months across covered assets
Pair Correlations : Performance Correlations with other assets
Beta : Volatility relative to the broad market
Performance Comparison : Visually compare/benchmark performance with other assets over time
Side-by-Side Comparison : Contrast with other assets over time in a side-by-side presentation
Sector : Health Care sector performance which includes Alnylam Pharmaceuticals Inc
Industry : Biotechnology industry performance which includes Alnylam Pharmaceuticals Inc